Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy

Scientific Reports

Volumn 1, Issue , 2011, Pages

  Hayashi, Takuma ^a,k   Horiuchi, Akiko ^b   Sano, Kenji ^c   Hiraoka, Nobuyoshi ^d   Kasai, Mari ^e   Ichimura, Tomoyuki ^e   Sudo, Tamotsu ^f   Tagawa, Yoh Ichi ^g   Nishimura, Ryuichiro ^f   Ishiko, Osamu ^e   Kanai, Yae ^d   Yaegashi, Nobuo ^h   Aburatani, Hiroyuki ⁱ   Shiozawa, Tanri ^b   Konishi, Ikuo ^j  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HYOGO CANCER CENTER   (Japan)

^g TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; GAMMA INTERFERON; LMP 2 PROTEIN; LMP-2 PROTEIN;

ANIMAL; ARTICLE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LEIOMYOSARCOMA; METABOLISM; MOUSE; MUTATION; MYOMETRIUM; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; UTERUS; UTERUS CANCER;

ANIMALS; CYSTEINE ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON-GAMMA; LEIOMYOSARCOMA; MICE; MUTATION; MYOMETRIUM; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UTERINE NEOPLASMS; UTERUS;

EID: 84859760026     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00180     Document Type: Article

References (61)

1. Zaloudek, C. & Hendrickson, M. R. Mesenchymal tumors of the uterus, in Kurman RJ. (ed): Blaustein's Pathology of the Female Genital Tract (ed 5).New York, Springer-Verlag 561-578 (2002).
2. Gadducci, A., et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol. Oncol. 62, 25-32 (1996). (Pubitemid 26234541)
3. Nordal, R. & Thoresen, S. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur. J. Cancer 33, 907-311 (1997).
4. Brooks, S. E., Zhan, M., Cote, T. & Baquet, C. R. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol. Oncol. 93, 204-208 (2004). (Pubitemid 38429571)
5. Dusenbery, K. E., Potish, R. A., Argenta, P. A. & Judson, P. L. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am. J. Clin. Oncol. 28, 295-300 (2005). (Pubitemid 40800483)
6. Wu, T. I., et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol. Oncol. 100, 166-172 (2006).
7. Leitao, M. M., et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 101, 1455-1462 (2004). (Pubitemid 39180402)
8. Perez, E. A., Pusztai, L. & Van de Vijver, M. Improving patient care through molecular diagnostics. Semin. Oncol. 31, 14-20 (2004). (Pubitemid 39370105)
9. Lin, J. F. & Slomovitz, B. M. Uterine sarcoma. Curr. Oncol. Rep. 10, 512-518 (2008).
10. Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D. & Vergote, I. Clinical management of uterine sarcomas. Lancet Oncol. 10, 1188-1198 (2009).
11. Miettinen, M. & Fetsch, J. F. Evaluation of biological potential of smooth muscle tumours. Histopathology 48, 97-105 (2006).
12. Muchamuel, T., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Med. 15, 781-788 (2009).
13. Van Kaer, L. et al. Altered peptidase and viral-specifi c T cell response in LMP2 mutant mice. Immunity 1, 533-541 (1994).
14. Hayashi, T. & Faustman, D. L. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res. 62, 24-27 (2002). (Pubitemid 34073979)
15. Hayashi, T., Kobayashi, Y., Kohsaka, S. & Sano, K. The mutation in the ATPbinding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene 25, 4016-4026 (2006). (Pubitemid 44024864)
16. Marques, J., Brucet, M., Lloberas, J. & Celada, A. STAT1 regulate lipopolysaccharide-and TNF-a-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J. Immunol. 173, 1103-1110 (2004). (Pubitemid 38924285)
17. Sizemore, N., et al. Inhibitor of kB kinase is required to activate a subset of interferon-c-stimulated genes. Proc. Natl. Acad. Sci. USA 101, 7994-7998 (2004). (Pubitemid 38698042)
18. Moschonas, A., et al. CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kB and of NFkB-mediated de novo synthesis of IRF-1. Mol. Cell Biol. 28, 6208-6222 (2008).
19. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. & Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kB. Nature 376, 167-170 (1995).
20. Parmar, S. & Platanias, L. C. Interferons. Cancer Treat. Res. 126, 45-68 (2005).
21. Platanias, L. C. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nature Rev. Immunol. 5, 375-386 (2005).
22. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001). (Pubitemid 32467045)
23. Bardelli, A., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003). (Pubitemid 36548874)
24. Futreal, P. A., et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004). (Pubitemid 38337497)
25. Stephens, P., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
26. Wang, Z., et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304, 1164-1166 (2004). (Pubitemid 38661854)
27. Parsons, D. W., et al. Colorectal cancer: Mutations in a signalling pathway. Nature 436, 792 (2005). (Pubitemid 41160630)
28. Hernando, E., et al. The AKT-mTOR. pathway plays a critical role in the development of leiomyosarcomas. Nature Med. 13, 748-753 (2007). (Pubitemid 46889749)
29. Mariani, O., et al. JUN. Oncogene Amplification and Overexpression Block Adipocytic Differentiation in Highly Aggressive Sarcomas. Cancer Cell 11, 361-374 (2007). (Pubitemid 46518313)
30. MOTIF Search profiling. http://motif. genome. jp
31. NCBI's Conserved Domain Database and Search Service, v2. 17 analysis. http://www. ncbi. nlm. nih. gov/Structure/cdd/cdd. shtml
32. Larramendy, M. L., Kaur, S., Svarvar, C., Böhling, T. & Knuutila, S. Gene copy number profiling of soft-tissue leiomyo-sarcomas by array comparative genome hybridization. Cancer Genet. Cytogen 169, 94-101 (2006). (Pubitemid 44308364)
33. Svarvar, C., et al. Do DNA copy number changes differentiate uterine from nonuterine leiomyosarcomas and predict metastasis? Modern Pathol. 19, 1068-1082 (2006). (Pubitemid 44106722)
34. Beck, A. H., et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29, 845-854 (2010).
35. Sexl, V., et al. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 101, 4937-4943 (2003). (Pubitemid 36857757)
36. Rodig, S. J., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373-383 (1998). (Pubitemid 28232082)
37. Horiuchi, A., et al. Reduced expression of calponin h1 in leiomyosarcoma of the uterus. Lab. Invest. 78, 839-846 (1998). (Pubitemid 28347880)
38. Hriuchi, A., Nikaido, T., Taniguchi, S. & Fujii, S. Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma. J. Natl. Cancer Inst. 91, 790-796 (1999). (Pubitemid 29239059)
39. Greten, F. R. & Karin, M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206, 193-199 (2004). (Pubitemid 38317289)
40. Pacifico, F. & Leonardi, A. NF-kappaB in solid tumors. Biochem. Pharmacol. 72, 1142-1152 (2006).
41. Perkins, N. D. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol. 14, 64-69 (2004).
42. Chen, F. & Castranova, V. Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res. 67, 11093-11098 (2007). (Pubitemid 350248529)
43. Hayashi, T. & Faustman, D. Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kB activation and prevention of tumor necrosis factor-alpha-induced apoptosis. J. Biol. Chem. 275, 5238-5247 (2000). (Pubitemid 30108929)
44. Wang, H. X., et al. Proteasome subunit LMP2 is required for matrix metalloproteinase-2 and-9 expression and activities in human invasive extravillous trophoblast cell line. J. Cell Physiol. 206, 616-623 (2006).
45. Kanamori, T., et al. PEP-19 overexpression in human uterine leiomyoma. Mol. Hum. Reprod. 9, 709-717 (2003). (Pubitemid 37483958)
46. Wang, L., et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol. Oncol. 90, 402-406 (2003). (Pubitemid 36952035)
47. Ylisaukko-oja, S. K., et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int. J. Cancer 119, 283-287 (2006).
48. Mittal, K. R., et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyomalike areas. Mod. Pathol. 10, 1303-1311 (2009).
49. Frentzel, S., et al. The major histocompatibility complex encoded beta-type proteasome subunits LMP2 and LMP7. Evidence that LMP2 and LMP7 are synthesized as proproteins and that cellular levels of both mRNA and LMPcontaining 20S proteasomes are differentially regulated. Eur. J. Biochem. 216, 119-26 (1993). (Pubitemid 23255178)
50. Choi, H. S., Seol, W. & Moore, D. D. A component of the 26S proteasome binds on orphan member of the nuclear hormone receptor superfamily. J. Steroid Biochem. Biol. 56, 23-30 (1996). (Pubitemid 26106507)
51. Zhang, H., et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription. EMBO J. 25, 4223-33 (2006). (Pubitemid 44435220)
52. Reits, E. A., Benham, A. M., Plougastel, B., Neefies, J. & Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 16, 6087-94 (1997). (Pubitemid 27458328)
53. Futreal, P. A., et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004). (Pubitemid 38337497)
54. Lengyel, E., Sawada, K. & Salgia, R. Tyrosine kinase mutations in human cancer. Curr. Mol. Med. 7, 77-84 (2007). (Pubitemid 46322280)
55. Pajares, M. J., et al. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 8, 349-357 (2007). (Pubitemid 46464532)
56. Hernando, E., et al. The AKT-mTOR. pathway plays a critical role in the development of leiomyosarcomas. Nature Med. 13, 748-753 (2007). (Pubitemid 46889749)
57. Mariani, O., et al. JUN. Oncogene Amplifi cation and Overexpression Block Adipocytic Differentiation in Highly Aggressive Sarcomas. Cancer Cell 11, 361-374 (2007). (Pubitemid 46518313)
58. Barretina, J., et al. Subtype-specific genomic alterations define new targets for softtissue sarcoma therapy. Nature Genet. 8, 715-721 (2010).
59. Chibon, F., et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nature Med. 16, 781-787 (2010).
60. Mikecz, A. V. The nuclear ubiquitin-proteasome system. J. Cell Science 119, 1977-1984 (2006).
61. Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Inve. 117, 1137-1196 (2007).